Extended Data Fig. 2: Kaplan-Meier estimates of progression-free survival.
From: Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Progression-free survival with nivolumab plus chemotherapy versus chemotherapy in patients with PD-L1 CPS ≥ 5 (a) and in all randomized patients (b). Progression-free survival with nivolumab plus ipilimumab versus chemotherapy in patients with PD-L1 CPS ≥ 5 (c) and in all randomized patients (d). aPer BICR. BICR, blinded independent central review; chemo, chemotherapy; CI, confidence interval; CPS, combined positive score; HR, hazard ratio; IPI, ipilimumab; mo, months; NIVO, nivolumab; PD-L1, programmed death ligand 1; PFS, progression-free survival.
